• The U.S. private equity firm owns 80 percent of Panasonic Healthcare and Panasonic Corp owns 20 percent. Panasonic Healthcare, KKR and Bayer all declined to comment. Bloomberg reported on Thursday that a sale to Panasonic Healthcare, which could be valued at between 1 billion and 2 billion euros, could be announced as soon as Friday.

  • The Google Glass-enabled ambulance  Friday, 20 Feb 2015 | 6:21 AM ET

    NBC's Charlie Wojciechowski reports how Google Glass is helping save lives.

  • LOS ANGELES— An 18- year-old student is one of the seven people infected by a "superbug" outbreak tied to contaminated medical instruments at a Los Angeles hospital, and he is struggling to avoid becoming the third to die, his attorney said. The young man as spent nearly three months in the hospital and is in grave condition after being infected with a potentially...

  • The surprise announcement offers a path forward for Google- backed genetic testing firm 23 andMe, which previously clashed with regulators over its direct-to-consumer technology. In the same announcement, the FDA said it cleared the first carrier screening test from 23 andMe, which was forced to pull its health tests from the market in 2013 due to a lack of...

  • Stopping the Superbug  Thursday, 19 Feb 2015 | 1:11 PM ET

    A new antibiotic-resistant "Superbug" may have contributed to the deaths of 2 patients at Ronald Reagan-UCLA Medical Center. Discussing the threat, with Dr. William Schaffner, Professor of Preventive Medicine at Vanderbilt.

  • Nearly 170 may be exposed to 'nightmare bacteria' Thursday, 19 Feb 2015 | 8:10 AM ET

    Over 160 patients may have been exposed to a "superbug" between last October and January, the UCLA Health System said Wednesday.

  • Regeneron: Need fair drug prices  Thursday, 19 Feb 2015 | 7:38 AM ET

    Regeneron founder Dr. Leonard Schleifer, expresses the need to have a dialogue around the price of medicine.

  • LOS ANGELES— A "superbug" outbreak suspected in the deaths of two Los Angeles hospital patients is raising disturbing questions about the design of a hard-to-clean medical instrument used on more than half a million people in the U.S. every year. At least seven people— two of whom died— have been infected with a potentially lethal, antibiotic-resistant strain of...

  • Why 'Allergan' will live on after Activis takeover Wednesday, 18 Feb 2015 | 8:46 AM ET
    Actavis pharmaceuticals

    Actavis can continue to perform while integrating Allergan into its business, CEO Brent Saunders tells CNBC.

  • Ron Klain, former U.S. Ebola czar, explains the safety and importance of vaccinating children to protect against measles.

  • Fmr. Ebola czar: $2 billion spent, US more prepared  Wednesday, 18 Feb 2015 | 8:13 AM ET

    Ron Klain, former U.S. Ebola czar, provides an update on the progress made to combat Ebola in West Africa, and the preparedness in America.

  • $20 million gift to St. Jude Children's Hospital  Wednesday, 18 Feb 2015 | 7:52 AM ET

    Eric Trump of The Trump Organization discusses his decision to give $20 million to St. Jude Children's Hospital to open a state of the art surgery and ICU facility.

  • Feb 17- Pharmacyclics Inc said its cancer drug developed with a Johnson& Johnson unit improved overall response rate in high-risk leukemia patients. About 115,000 patients suffer from CLL in the United States and about 16,000 are newly diagnosed each year. Shares of Pharmacyclics were up 1.4 percent at $165.69 in early trading on the Nasdaq.

  • Feb 14- New York Times media columnist David Carr, a beloved and widely respected journalist who wrote a memoir about his struggles with addiction, died of lung cancer and cardiovascular disease, New York City's medical examiner said on Saturday. In addition to his weekly column, Carr reported for the paper's culture section and featured prominently in "Page One:...

  • Measle-con Valley  Thursday, 12 Feb 2015 | 1:02 PM ET

    Joanna Pearlstein, Wired, provides insight to "sickeningly low" vaccination rates at day care centers across Silicon Valley.

  • UPDATE 1-Novavax starts Ebola vaccine trial in humans Thursday, 12 Feb 2015 | 12:06 PM ET

    Feb 12- Novavax Inc has begun early-stage human trials of an Ebola vaccine that it hopes can win the race to become the most effective shot for the deadly virus. The company has the means to manufacture millions of doses of the vaccine every month and is seeking funding to develop it further, Chief Executive Stanley Erck told Reuters. Even as President Barack Obama...

  • The case of the 'anti-vaccine elitism' Thursday, 12 Feb 2015 | 11:04 AM ET
    Vials of measles, mumps and rubella vaccine are displayed on a counter at a Walgreens Pharmacy on January 26, 2015 in Mill Valley, California.

    Could vaccine compliance be correlated with income level and elitism?

  • Novavax starts Ebola vaccine trial in humans Thursday, 12 Feb 2015 | 8:27 AM ET

    Feb 12- Novavax Inc has begun early-stage testing of its Ebola vaccine in humans, the company said, less than five months after entering the race to develop a shot for the deadly virus. Other potential vaccines include those being developed by a NewLink Genetics Corp and Merck& Co Inc collaboration and by Johnson& Johnson and Bavarian Nordic A/S.

  • University of Florida researchers reported findings from a two-year study using the diabetes drug metformin in mice and human blood cells in a laboratory setting in the journal Science Translational Medicine. The findings could become a new treatment option for lupus, for which there is no cure, according to a news release from the University of Florida.

  • Tech company wants to help hospitals save millions  Wednesday, 11 Feb 2015 | 11:50 AM ET

    Mark Slaughter, Cohealo Inc. founder and CEO, explains how his company is helping hospitals share underutilized medical equipment.